Carrier Screening Market
Carrier Screening Market by Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices, Others), by Regions (North America, Europe, Asia Pacific, Middle East & Africa) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)
|Forecast Years for Carrier Screening Market:||2022 - 2028|
|Historical Years for Carrier Screening Market:||2016 - 2021|
|Revenue 2021 for Carrier Screening Market:||USD 2.21 Billion|
|Revenue 2028 for Carrier Screening:||USD 7.56 Billion|
|Revenue CAGR (2022 - 2028) for Carrier Screening Market :||17.3%|
|Fastest Growing Region (2022 - 2028) for Carrier Screening Market:||Asia Pacific|
|Largest Region (2021) for Carrier Screening Market:||North America|
Carrier Screening Market: By Product and Service, Type, Medical Condition, Technology End User, and Region
Global Carrier Screening market is valued at USD 2.21 Billion in 2021 and is projected to reach a value of USD 7.56 Billion by 2028 at a CAGR of 17.3% during the forecast period, 2022–2028.
The medical industry has developed rapidly in the past few decades, with scientific discoveries leading to new hypochondriacal illnesses. Most of these are not deadly diseases but are especially frequent among the population between 20 and 50 years old. This is because this group often neglects preventive checks or already display symptoms close to those of a serious illness thus being treated initially under false diagnosis. For example, many people think that any persistent cold symptom should be examined by a physician right away. The large number of diagnosed cases highlights just how important it is that children’s primary care physicians up their game in communicating both the benefits and the risks attendant to Carrier Screening for recessive genetic disorders, including cystic fibrosis (CF).
Recent Development in Carrier Screening is Playing Key Role in Development of Carrier Screening Market
It has been stated many times by different people within the medical field that due to recent developments in the field, carrier testing should become mandatory when couples get married or even much earlier than this point so they can fully understand what risks they could face if they decide to conceive. However, there are still far too many people who are unaware of the benefits to Carrier Screening and how it can be beneficial in avoiding any complications further down the line.
This is also true within certain religious groups where if couples were made aware of the risks that they could face when conceiving or having children then this would make them more likely to go for carrier testing, especially when considering their faith. Due to this fact, there may be an increased demand for pre-conception genetic counseling services and/or Carrier Screening in these communities as well as in families who do not have a history of serious disease but want to ensure they avoid passing on recessive traits which are routinely screened for during pregnancy, such as cystic fibrosis (CF), sickle cell anaemia, thalassaemia, spinal muscular atrophy and Fragile X syndrome. In the UK alone there are around 100 recessive diseases which could be screened for before conception or during early pregnancy to prevent a significant number of miscarriages and stillbirths as well as a large proportion of children being born with a serious health condition which can decrease life expectancy.
The global Carrier Screening market is segmented into type, technology, and end user. On the basis of types the market is segmented into expanded Carrier Screening and targeted disease Carrier Screening. In terms of technology, the market is bifurcated into DNA sequencing, polymerase chain reaction, microarrays, and others. Based on end user the market is segmented into hospitals & clinics, reference laboratories, physician offices, and others.
Below tree is interactive. You can click the nodes to get more information.
Expanded Carrier Screening to dominate the Market
Based on Carrier Screening type, the market is segmented into expanded Carrier Screening and targeted disease Carrier Screening. The expanded Carrier Screening holds the major share in the global market owing to advancement in polymerase chain reaction, DNA sequencing, microarrays, and other technologies in Carrier Screening.
The report also states that demand for Carrier Screening is likely to increase markedly as multiplex ligation-dependent probe amplification (MLPA) becomes more widely available to detect large rearrangements associated with hemoglobinopathies such as sickle cell disease, β-thalassemia and α-thalassemia. Currently Carrier Screening is usually performed using biochemical methods which include high performance liquid chromatography (HPLC) or DNA sequencing.
North America and Europe are the Largest Carrier Screening Market
The Carrier Screening market in North America will see a double-digit annual growth over the next few years, largely driven by advances in sequencing technology and growing demand for molecular diagnostics tests. The growth is further supported by increase in Carrier Screening and pre-marital Carrier Screening tests. More than 80% of all carrier testing takes place in Europe, North America, Australia and New Zealand because of the presence of a well-developed healthcare infrastructure with reimbursement for Carrier Screening tests for thalassemia major.
Some of the key players in the global Carrier Screening are Invitae (US), Eurofins Scientific (US), Fulgent Genetics (US), OPKO Health (US), Quest Diagnostics (US), Myriad Genetics (US), Sema4 (US), Thermo Fisher Scientific (US) and Illumina (US), among others.
The Carrier Screening is Segmented as Follows:
Regions & Countries Covered
Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Frequently Asked Questions
the global demand for Carrier Screening
in terms of revenue?
The global Carrier Screening valued at USD 2.21 Billion in 2020 and is expected to reach USD 7.56 Billion in 2028 growing at a CAGR of 17.3%
are the prominent players
in the market?
The prominent players in the market are Invitae (US), Eurofins Scientific (US), Fulgent Genetics (US), OPKO Health (US), Quest Diagnostics (US), Myriad Genetics (US), Sema4 (US), Thermo Fisher Scientific (US) and Illumina (US).
At what CAGR is the market projected to grow within the forecast period?
The market is project to grow at a CAGR of 17.3% between 2021 and 2028.
the driving factors
fueling the growth of the market.
The driving factors of the Carrier Screening include
- Recent Development in Carrier Screening is Playing Key Role in Development of Carrier Screening Market
region accounted for the
largest share in the market?
North America was the leading regional segment of the Carrier Screening in 2020.